The GPC1 Knockout HeLa Polyclonal Cells product provides a heterogeneous population of CRISPR/Cas9-edited HeLa cells carrying targeted disruptions in the human GPC1 gene. As a polyclonal knockout pool, the cells reflect a spectrum of editing events generated by CRISPR/Cas9-mediated gene disruption, avoiding clonal selection biases while enabling robust loss-of-function analyses. This format is ideal for studying GPC1 function in a physiologically relevant, immortalized epithelial background. The cells are supplied as a proliferating culture, ready for use in downstream experimental workflows, including signaling assays, phenotypic screens, and target validation studies.
HeLa cells, derived from a human cervical adenocarcinoma, are one of the most widely utilized cell lines in biomedical research. Their robust proliferation, ease of genetic manipulation, and well-characterized signaling pathways make them an excellent host for gene-editing studies. As an epithelial cell model, HeLa cells endogenously express a repertoire of growth factor receptors and signaling effectors that intersect with GPC1-mediated pathways, providing a relevant context for interrogating heparan sulfate proteoglycan biology in cancer.
GPC1 encodes a glycosylphosphatidylinositol-anchored cell surface heparan sulfate proteoglycan that acts as a co-receptor for heparin-binding growth factors, including FGF2, HGF, and VEGF. By stabilizing interactions with receptors like FGFR1 and c-Met, GPC1 potentiates MAPK/ERK (ERK1/2) and PI3K/AKT (AKT) signaling. It also modulates Wnt pathways by stabilizing ??-catenin and upregulating MYC, and contributes to Hedgehog signaling via Shh-Patched-Gli1. Upstream regulators include Wnt3a, FGF2, and SOX9, while interacting partners encompass Slit/Robo and other morphogens, highlighting its broad signaling roles.
In HeLa cells, GPC1 knockout disrupts signaling networks that sustain malignant phenotypes. Loss of GPC1 attenuates ERK and AKT phosphorylation, reduces ??-catenin-dependent transcription, and impairs Gli1-mediated responses, leading to decreased proliferation, migration, and tumorigenic potential. This polyclonal knockout thus serves as a robust model for studying heparan sulfate proteoglycan function in cervical adenocarcinoma and for comparative analyses across other GPC1-associated cancers, including pancreatic adenocarcinoma, glioma, and breast cancer.
Researchers can employ these cells in diverse applications, including western blotting for phospho-ERK, phospho-AKT, and ??-catenin; RT-qPCR for pathway targets; and luciferase reporters for Wnt/??-catenin activity. Proliferation (MTT, BrdU), migration (wound healing, transwell), and invasion assays interrogate phenotypic consequences, while flow cytometry quantifies cell surface GPC1. Co-immunoprecipitation, drug sensitivity, and apoptosis assays support target validation and mechanistic studies. Applications in exosome and biomarker research leverage the cells for heparan sulfate proteoglycan analysis. For inquiries, contact Ascent Research.
